REFERENCES
1. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of
aortic-valve sclerosis with cardiovascular mortality and morbidity in
the elderly. N Engl J Med. 1999;341(3):142-7.
2. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang
OW, et al. A prospective survey of patients with valvular heart disease
in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J.
2003;24(13):1231-43.
3. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,
Enriquez-Sarano M. Burden of valvular heart diseases: a population-based
study. Lancet. 2006;368(9540):1005-11.
4. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al.
2017 ESC/EACTS Guidelines for the management of valvular heart disease.
Eur Heart J. 2017;38(36):2739-91.
5. Elzeneini M, Assaf Y, Aalaei-Andabili SH, Mahmoud A, Hamburger R,
Goel R, et al. Predictors of ventricular pacing burden after permanent
pacemaker implantation following transcatheter aortic valve replacement.
Clin Cardiol. 2020.
6. Ravaux JM, Di Mauro M, Vernooy K, Kats S, Mariani S, Ronco D, et al.
Permanent pacemaker implantation following transcatheter aortic valve
implantation using self-expandable, balloon-expandable, or mechanically
expandable devices: a network meta-analysis. Europace.
2021;23(12):1998-2009.
7. Bisson A, Bodin A, Herbert J, Lacour T, Saint Etienne C, Pierre B, et
al. Pacemaker Implantation After Balloon- or Self-Expandable
Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis.
J Am Heart Assoc. 2020;9(9):e015896.
8. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, et
al. Assessment of valvular calcification and inflammation by positron
emission tomography in patients with aortic stenosis. Circulation.
2012;125(1):76-86.
9. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and
cardiovascular diseases: an update. Expert Rev Cardiovasc Ther.
2016;14(5):573-7.
10. Avci A, Elnur A, Goksel A, Serdar F, Servet I, Atilla K, et al. The
relationship between neutrophil/lymphocyte ratio and calcific aortic
stenosis. Echocardiography. 2014;31(9):1031-5.
11. Cho KI, Cho SH, Her AY, Singh GB, Shin ES. Prognostic Utility of
Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients
with Severe Calcific Aortic Stenosis. PLoS One. 2016;11(8):e0161530.
12. Reinders A. DVCS, Joubert G. Pre-interventional assessment and
calcification score of the aortic valve and annulus, with multi-detector
CT, in transcatheter aortic valve implantation (TAVI) using the
Medtronic CoreValve. S Afr J Rad. 2015.
13. Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Glikson M, et
al. Inverse Relationship Between Membranous Septal Length and the Risk
of Atrioventricular Block in Patients Undergoing Transcatheter Aortic
Valve Implantation. JACC Cardiovasc Interv. 2015;8(9):1218-28.
14. Cote N, Mahmut A, Bosse Y, Couture C, Page S, Trahan S, et al.
Inflammation is associated with the remodeling of calcific aortic valve
disease. Inflammation. 2013;36(3):573-81.
15. Stone PA, Kazil J. The relationships between serum C-reactive
protein level and risk and progression of coronary and carotid
atherosclerosis. Semin Vasc Surg. 2014;27(3-4):138-42.
16. Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, et
al. Clinical factors, but not C-reactive protein, predict progression of
calcific aortic-valve disease: the Cardiovascular Health Study. J Am
Coll Cardiol. 2007;50(20):1992-8.
17. Imai K, Okura H, Kume T, Yamada R, Miyamoto Y, Kawamoto T, et al.
C-Reactive protein predicts severity, progression, and prognosis of
asymptomatic aortic valve stenosis. Am Heart J. 2008;156(4):713-8.
18. Iglesias-Alvarez D, Lopez-Otero D, Gonzalez-Ferreiro R,
Sanmartin-Pena X, Cid-Alvarez B, Trillo-Nouche R, et al. Prognostic
Value of hs-CRP After Transcatheter Aortic Valve Implantation. Circ
Cardiovasc Interv. 2018;11(12):e007213.
19. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role
of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269-85.